Inhibition of opioid-degrading enzymes potentiates delta9-tetrahydrocannabinol-induced antinociception in mice.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Neuropharmacology

• Publication date

  1998-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0028-3908(98)00005-7PMID 9680246
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Potentiation of Δ9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of μ- and κ-opioid receptors

  1996cited by this paper
• A role for central cannabinoid and opioid systems in peripheral delta 9-tetrahydrocannabinol-induced analgesia in mice.

  1996cited by this paper
• Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement.

  1996cited by this paper
• In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity.

  1996cited by this paper
• The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord.

  1996cited by this paper
• Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu- and kappa-opioid receptors.

  1996cited by this paper
• Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine.

  1995cited by this paper
• Antisense oligodeoxynucleotides to the kappa-1 receptor block the antinociceptive effects of delta 9-THC in the spinal cord.

  1995cited by this paper
• Degradation of Dynorphin‐Related Peptides by the Puromycin‐Sensitive Aminopeptidase and Aminopeptidase M

  1995cited by this paper
• AM630, a competitive cannabinoid receptor antagonist.

  1995cited by this paper
• Antisense oligodeoxynucleotides to the κ-1 receptor block the antinociceptive effects of Δ9-THC in the spinal cord

  1995cited by this paper
• Cloning and sequencing of a cDNA encoding the mouse brain-type cannabinoid receptor protein.

  1995cited by this paper
• Formation and inactivation of endogenous cannabinoid anandamide in central neurons

  1994cited by this paper
• SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

  1994cited by this paper
• Molecular cloning and functional expression of a mu opioid receptor from rat brain

  1994cited by this paper
• Developmental expression of cannabinoid receptor mRNA.

  1993cited by this paper
• Molecular characterization of a peripheral receptor for cannabinoids

  1993cited by this paper
• Hypoalgesic action of bestatin analogues that inhibit central aminopeptidases, but not neutral endopeptidase.

  1993cited by this paper
• Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice.

  1993cited by this paper
• Characterization and autoradiographic localization of the cannabinoid binding site in rat brain using [3H]11-OH-delta 9-THC-DMH.

  1992cited by this paper
• In vivo occupation of mouse brain opioid receptors by endogenous enkephalins: blockade of enkephalin degrading enzymes by RB 101 inhibits [3H]diprenorphine binding.

  1992cited by this paper
• Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

  1992cited by this paper
• Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice.

  1992cited by this paper
• Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats.

  1992cited by this paper
• Marijuana's interaction with brain reward systems: update 1991.

  1991cited by this paper
• Systemic administration of (Tyr-D-Ser(O-tert-butyl)-Gly-Phe-Leu-Thr(O-tert-butyl), a highly selective delta opioid agonist, induces mu receptor-mediated analgesia in mice.

  1991cited by this paper
• Structure of a cannabinoid receptor and functional expression of the cloned cDNA

  1990cited by this paper
• The antinociceptive effects of SCH-32615, a neutral endopeptidase (enkephalinase) inhibitor, microinjected into the periaqueductal, ventral medulla and amygdala.

  1990cited by this paper
• Changes in levels of the tripeptide Tyr-Gly-Gly as an index of enkephalin release in the spinal cord: effects of noxious stimuli and parenterally-active peptidase inhibitors.

  1989cited by this paper
• Determination and characterization of a cannabinoid receptor in rat brain.

  1988cited by this paper
• The degradation of dynorphin A in brain tissue in vivo and in vitro.

  1987cited by this paper
• Characterization of aminopeptidases responsible for inactivating endogenous (Met5)enkephalin in brain slices using peptidase inhibitors and anti-aminopeptidase M antibodies.

  1986cited by this paper
• Analgesic effects of kelatorphan, a new highly potent inhibitor of multiple enkephalin degrading enzymes.

  1984cited by this paper
• The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice

  1980cited by this paper
• Intrathecal morphine in mice: a new technique.

  1980cited by this paper
• Endogenous opioid peptides: multiple agonists and receptors

  1977cited by this paper
• Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse.

  1957cited by this paper
• Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines.

  1953cited by this paper
• A simplified method of evaluating dose-effect experiments.

  1948cited by this paper
• A METHOD FOR DETERMINING LOSS OF PAIN SENSATION

  1941cited by this paper

• Cannabinoid Analgesia in Postoperative Pain Management: From Molecular Mechanisms to Clinical Reality

  2024cites this paper
• Polarization Controlled Assembly of Ultrathin Thiorphan Nanostructures on ZnO Surface Facets.

  2023cites this paper
• Peptide Neurotransmitters and Hormones

  2020cites this paper
• Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependence.

  2018cites this paper
• Acute foot-shock stress decreased seizure susceptibility against pentylenetetrazole-induced seizures in mice: Interaction between endogenous opioids and cannabinoids.

  2018cites this paper
• The major neurotransmitter systems in the basolateral amygdala and the ventral tegmental area mediate morphine-induced memory consolidation impairment.

  2017cites this paper
• Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System

  2014cites this paper
• Effects of neuropeptide FF system on CB₁ and CB₂ receptors mediated antinociception in mice.

  2012cites this paper
• Cannabinoid-opioid interactions during neuropathic pain and analgesia.

  2010cites this paper
• The Analgesic Activity of Bestatin as a Potent APN Inhibitor

  2010cites this paper
• One step closer to the role of the brain CB2 cannabinoid receptors: interaction with the μ-opioid system

  2008cites this paper
• Molecular and cellular basis of cannabinoid and opioid interactions.

  2005cites this paper
• The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice.

  2004cites this paper
• Modulation of morphine-induced Fos-immunoreactivity by the cannabinoid receptor antagonist SR 141716.

  2004cites this paper
• Gender differences in proenkephalin gene expression response to ∆9-tetrahydrocannabinol in the hypothalamus of the rat

  2002cites this paper
• Cannabinoid receptors and pain.

  2001cites this paper
• Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse.

  2001cites this paper
• Neurobiología de la drogadicción. Cannabis

  2001cites this paper
• Cannabinoids modulate pain by multiple mechanisms of action

  2000cites this paper
• DL-phenylalanine markedly potentiates opiate analgesia - an example of nutrient/pharmaceutical up-regulation of the endogenous analgesia system.

  2000cites this paper
• Cannabinoid and kappa opioid receptors reduce potassium K current via activation of G(s) proteins in cultured hippocampal neurons.

  2000cites this paper
• Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats.

  1999cites this paper
• From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis.

  1999cites this paper
• Repeated administration of delta9-tetrahydrocannabinol produces a differential time related responsiveness on proenkephalin, proopiomelanocortin and corticotropin releasing factor gene expression in the hypothalamus and pituitary gland of the rat.

  1999cites this paper
• Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of Δ9-tetrahydrocannabinol in rats

  1999cites this paper
• Time-dependent differences of repeated administration with Delta9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu-opioid and CB1-cannabinoid receptors in the caudate-putamen.

  1999cites this paper
• Pharmacological and biochemical interactions between opioids and cannabinoids.

  1999cites this paper